CN114181310B - 抗tigit抗体、其药物组合物及用途 - Google Patents

抗tigit抗体、其药物组合物及用途 Download PDF

Info

Publication number
CN114181310B
CN114181310B CN202210132762.1A CN202210132762A CN114181310B CN 114181310 B CN114181310 B CN 114181310B CN 202210132762 A CN202210132762 A CN 202210132762A CN 114181310 B CN114181310 B CN 114181310B
Authority
CN
China
Prior art keywords
antibody
seq
tigit
antigen
vegfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210132762.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114181310A (zh
Inventor
夏瑜
王忠民
李百勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202210132762.1A priority Critical patent/CN114181310B/zh
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of CN114181310A publication Critical patent/CN114181310A/zh
Application granted granted Critical
Publication of CN114181310B publication Critical patent/CN114181310B/zh
Priority to PCT/CN2023/075862 priority patent/WO2023151693A1/zh
Priority to MX2024009976A priority patent/MX2024009976A/es
Priority to IL314785A priority patent/IL314785A/en
Priority to KR1020247026551A priority patent/KR20240145470A/ko
Priority to CA3208430A priority patent/CA3208430A1/en
Priority to JP2023547446A priority patent/JP2025506318A/ja
Priority to US18/264,138 priority patent/US20250034253A1/en
Priority to EP23745373.3A priority patent/EP4273170A4/en
Priority to AU2023217806A priority patent/AU2023217806A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202210132762.1A 2022-02-14 2022-02-14 抗tigit抗体、其药物组合物及用途 Active CN114181310B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202210132762.1A CN114181310B (zh) 2022-02-14 2022-02-14 抗tigit抗体、其药物组合物及用途
AU2023217806A AU2023217806A1 (en) 2022-02-14 2023-02-14 Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
PCT/CN2023/075862 WO2023151693A1 (zh) 2022-02-14 2023-02-14 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途
EP23745373.3A EP4273170A4 (en) 2022-02-14 2023-02-14 Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
MX2024009976A MX2024009976A (es) 2022-02-14 2023-02-14 Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso.
IL314785A IL314785A (en) 2022-02-14 2023-02-14 Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1/anti-vegfa bispecific antibody, and use thereof
KR1020247026551A KR20240145470A (ko) 2022-02-14 2023-02-14 항-tigit 항체 및 항-pd-1/항-vegfa 이중특이적 항체를 포함하는 약제학적 조성물 및 용도
CA3208430A CA3208430A1 (en) 2022-02-14 2023-02-14 Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1/anti-vegfa bispecific antibody, and use thereof
JP2023547446A JP2025506318A (ja) 2022-02-14 2023-02-14 抗tigit抗体と抗pd-1-抗vegfa二重特異性抗体を含有する医薬組成物及び使用
US18/264,138 US20250034253A1 (en) 2022-02-14 2023-02-14 Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1/anti-vegfa bispecific antibody, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210132762.1A CN114181310B (zh) 2022-02-14 2022-02-14 抗tigit抗体、其药物组合物及用途

Publications (2)

Publication Number Publication Date
CN114181310A CN114181310A (zh) 2022-03-15
CN114181310B true CN114181310B (zh) 2022-07-05

Family

ID=80607015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210132762.1A Active CN114181310B (zh) 2022-02-14 2022-02-14 抗tigit抗体、其药物组合物及用途

Country Status (10)

Country Link
US (1) US20250034253A1 (cg-RX-API-DMAC7.html)
EP (1) EP4273170A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506318A (cg-RX-API-DMAC7.html)
KR (1) KR20240145470A (cg-RX-API-DMAC7.html)
CN (1) CN114181310B (cg-RX-API-DMAC7.html)
AU (1) AU2023217806A1 (cg-RX-API-DMAC7.html)
CA (1) CA3208430A1 (cg-RX-API-DMAC7.html)
IL (1) IL314785A (cg-RX-API-DMAC7.html)
MX (1) MX2024009976A (cg-RX-API-DMAC7.html)
WO (1) WO2023151693A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
US20240352153A1 (en) * 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
KR20240046905A (ko) * 2021-08-20 2024-04-11 아케소 바이오파마, 인크. 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
CN117003883A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合tigit和vegf的双特异性分子及其用途
CN116284395B (zh) * 2022-12-12 2024-11-08 合肥天港免疫药物有限公司 抗cd155的抗体及其应用
KR20250112917A (ko) * 2022-12-12 2025-07-24 라노바 메디신즈 리미티드 Pd1 및 vegf를 표적으로 하는 이중특이적 항체
CN116143923B (zh) * 2022-12-30 2025-11-11 合肥天港免疫药物有限公司 高亲和力tigit抗体及其应用
IL322840A (en) * 2023-02-20 2025-10-01 Akeso Biopharma Co Ltd Fusion protein comprising a TGF-βRII extracellular region fragment, its pharmaceutical composition and use
KR20260074706A (ko) * 2023-09-14 2026-05-26 아케소 바이오파마 컴퍼니 리미티드 약물 조합 및 그 용도
WO2025140188A1 (zh) * 2023-12-29 2025-07-03 成都优洛生物科技有限公司 抗tl1a抗体或其抗原结合片段及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355965A (zh) * 2005-06-08 2009-01-28 达纳-法伯癌症研究院 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
CN104479018A (zh) * 2008-12-09 2015-04-01 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
LT3618863T (lt) * 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
CN111051347B (zh) * 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
MX2022006330A (es) * 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
CN110960543A (zh) * 2019-12-10 2020-04-07 安徽瀚海博兴生物技术有限公司 一种联合抗vegf-抗pd1双特异性抗体用于制备抗癌药物
TWI813934B (zh) * 2020-01-21 2023-09-01 大陸商甫康(上海)健康科技有限責任公司 一種雙特異性抗pd-l1/vegf抗體及其用途
IL294800A (en) * 2020-01-27 2022-09-01 Genentech Inc Methods of treating cancer with an antibody to an anti-ti antagonist
WO2021263085A2 (en) * 2020-06-25 2021-12-30 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
CA3189730A1 (en) * 2020-08-05 2022-02-10 Crystal Bioscience Inc. Anti-tigit antibody and methods of use thereof
US11028172B1 (en) * 2020-11-10 2021-06-08 Lepu Biopharma Co., Ltd. Anti-TIGIT antibodies and uses thereof
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355965A (zh) * 2005-06-08 2009-01-28 达纳-法伯癌症研究院 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
CN104479018A (zh) * 2008-12-09 2015-04-01 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体
CN113583131A (zh) * 2014-08-19 2021-11-02 默沙东公司 抗tigit抗体

Also Published As

Publication number Publication date
US20250034253A1 (en) 2025-01-30
EP4273170A4 (en) 2025-02-19
WO2023151693A1 (zh) 2023-08-17
EP4273170A1 (en) 2023-11-08
CN114181310A (zh) 2022-03-15
KR20240145470A (ko) 2024-10-07
JP2025506318A (ja) 2025-03-11
IL314785A (en) 2024-10-01
MX2024009976A (es) 2024-08-26
AU2023217806A1 (en) 2024-09-12
CA3208430A1 (en) 2023-08-14

Similar Documents

Publication Publication Date Title
CN107922503B (zh) 一种pdl-1抗体、其药物组合物及其用途
EP3443009B1 (en) Anti-tim-3 antibodies and compositions
EP3368572B9 (en) Anti-pd-1 antibodies and compositions
US20250034253A1 (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1/anti-vegfa bispecific antibody, and use thereof
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
US20240352153A1 (en) Pharmaceutical composition and use
CN114981301B (zh) Pd1和vegfr2双结合剂
CN114478769B (zh) 抗tigit抗体、其药物组合物及用途
CN114106182B (zh) 抗tigit的抗体及其用途
EP4321537A1 (en) Pharmaceutical composition and use thereof
CN120603856A (zh) 三特异性抗原结合分子及其应用
HK40100877A (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
HK40089230A (en) Pharmaceutical composition and use
HK40129144A (en) Anti-il-1rap antibody, and pharmaceutical composition and use thereof
HK40096182A (en) Pharmaceutical composition and use thereof
HK40085294A (en) Anti-pd-1 antibodies and compositions
EA053336B1 (ru) Фармацевтическая композиция и применение
HK40000742B (en) Anti-tim-3 antibodies and compositions
HK1256846A1 (en) Anti-pd-1 antibodies and compositions
HK1256846B (en) Anti-pd-1 antibodies and compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant